These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 2872958)

  • 1. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
    Hamilton CA; Reid JL; Vincent J
    Br J Pharmacol; 1985 Sep; 86(1):79-87. PubMed ID: 2864970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.
    Elliott HL; Meredith PA; Sumner DJ; McLean K; Reid JL
    Br J Clin Pharmacol; 1982 May; 13(5):699-703. PubMed ID: 6123342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
    Hayduk K; Schneider HT
    Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist.
    de Leeuw PW; Ligthart JJ; Smout AJ; Birkenhäger WH
    Eur J Clin Pharmacol; 1982; 23(5):397-401. PubMed ID: 6129979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of alpha-blockers in the management of hypertension: a practical view.
    McInnes GT
    J Hum Hypertens; 1991 Aug; 5(4):313-6. PubMed ID: 1683406
    [No Abstract]   [Full Text] [Related]  

  • 10. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
    Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
    Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
    Louis WJ; McNeil JJ; Anavekar SN; Conway EL; Workman B; Howes LG; Drummer OH; Jarrott B
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S100-3. PubMed ID: 2455158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
    Agabiti-Rosei E; Muiesan ML; Rizzoni D; Zulli R; Calebich S; Beschi M; Castellano M; Muiesan G
    J Hum Hypertens; 1992 Feb; 6(1):9-15. PubMed ID: 1349920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxazosin: a new alpha 1-adrenergic antagonist.
    Babamoto KS; Hirokawa WT
    Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.